GridAI Technologies Corp. reported significant financial challenges in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded a net loss of approximately $13.0 million for the three months ended June 30, 2026, compared to a loss of $1.0 million in the same period last year. For the six months, the net loss was approximately $16.5 million, up from $2.3 million in the prior year. The increase in losses is attributed to a goodwill impairment charge of $10.1 million, reflecting delays in the commercialization of its AI-driven energy technology business following the acquisition of Grid AI Corp. in September 2025.

In terms of revenue, GridAI reported $85,876 for the three months ended June 30, 2026, all of which came from its AI segment, marking a notable shift as the company had not generated revenue in the previous year. For the six-month period, total revenue reached $124,084, again solely from the AI segment. The company’s cost of services for the six months was approximately $774,338, leading to a gross loss of $650,254. The increase in operating expenses, which totaled $16.1 million for the six months, was primarily driven by general and administrative costs associated with the integration of Grid AI and increased professional fees.

Operationally, GridAI has undergone significant changes, including the acquisition of Grid AI Corp., which has expanded its focus to include AI-driven energy optimization technologies. However, the company has also faced setbacks, such as the rescission of its merger with ImmunogenX, which resulted in the loss of associated assets and liabilities. As of June 30, 2026, the company reported total assets of $37.0 million, down from $48.6 million at the end of 2025, largely due to the impairment of goodwill and other intangible assets.

Looking ahead, GridAI Technologies Corp. faces substantial liquidity challenges, with cash and cash equivalents of approximately $1.4 million and a working capital deficit of about $11.8 million. The company has indicated that it will need to secure additional funding to continue operations and execute its business plan. Management has expressed concerns about its ability to continue as a going concern without raising further capital, which may include equity or debt financing, warrant exercises, or other strategic transactions. The company’s future performance will depend on its ability to navigate these financial hurdles while pursuing growth in its AI-driven energy technology segment.

About GridAI Technologies Corp.

Entero Therapeutics, Inc. develops targeted, non-systemic therapies for gastrointestinal diseases, focusing on locally acting biologics like Adrulipase for exocrine pancreatic insufficiency in cystic fibrosis and chronic pancreatitis. The company advances its products through clinical trials, leveraging proprietary enzymes and formulations, and operates in regulated markets worldwide. It emphasizes innovative drug delivery, intellectual property protection, and strategic collaborations within the biopharmaceutical industry.

This description was generated via AI from an annual report. Updated about 1 year ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.

View the complete official filing on the SEC website.

Read on SEC.gov